Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
XLOthis companyXilio Therapeutics, Inc.	$8.69	-2.14×	2.12×	1.71×	1.66×	3965.9%	96.5%	-95.9%	-80.1%	-99.3%	-42.1%	-7.4%	0.2×	3.9×	0×	2.58×	0.0%	3	-2.75	2	B-
ALGSAligos Therapeutics, Inc.	$4.38	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
ATNMActinium Pharmaceuticals, Inc.	$1.60	-1.25×	5.42×	471.4×	0.12×	0.8%	100.0%	-40274.4%	-37652.2%	-432.6%	-81.4%	-58.2%	0.22×	1.4×	0×	6.2×	0.0%	4	-8.02	5	S-
OKUROnKure Therapeutics, Inc.	$2.88	-0.66×	0.7×	0×	0.33×	63.3%	0.0%	0.0%	0.0%	-105.9%	-110.9%	-132.3%	0.01×	1×	0×	10.28×	0.0%	2	6.84	3	B
PDSBPDS Biotechnology Corporation	$1.12	-1.04×	3.86×	0×	-0.86×	-89.5%	0.0%	0.0%	0.0%	-372.9%	-116.5%	-77.7%	1.83×	0.32×	-5.91×	2.98×	0.0%	2	-44.34	2	C
SKYESkye Bioscience, Inc.	$0.87	-0.53×	1.49×	0×	-0.44×	-40.6%	0.0%	0.0%	0.0%	-279.3%	-286.6%	-144.8%	0.01×	0.1×	0×	3.3×	0.0%	1	-41.52	2	C+
Peer median	—	-1.04×	1.72×	0×	-0.44×	-40.6%	0.0%	0.0%	0.0%	-279.3%	-116.5%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	—